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ABSTRACT 
 
Background: Orofacial clefts (OFC) are among the most common congenital 
anomalies worldwide and carry a great burden for those children affected. Recent 
studies have identified the possibility of positive links between maternal 
diabetes/abnormal glucose metabolism and maternal overweight/obesity with the 
occurrence of orofacial clefts in their offspring. Further investigation into these 
possible aetiological factors is warranted in order to inform preventative strategies 
against OFC. 
Aims: The aim of this study is to investigate the association between oral cleft in 
children and abnormal glucose metabolism and obesity in their mothers in the 
Tayside population. This will provide unique pilot data to inform a future Scotland 
wide study. 
Design and Setting: A case-control record linkage study undertaken at the 
University of Dundee during 2011–2013. 
Materials and Methods: Information regarding 138 mothers of infants born with 
OFC in the Tayside area between 1990–2010 was identified and anonymised using 
the CLEFTSiS database. This was linked to further healthcare datasets held within 
NHS Tayside and compared with corresponding datasets regarding 564 matched 
control mothers. The possibility of a significant difference in the proportion of 
diabetic case mothers compared to control mothers was analysed using a chi-
squared test. Possible differences between maternal glycosylated haemoglobin 
levels and weight were assessed for significance using an independent samples t-
test. 
Results: Completeness of datasets was found to be poor regarding maternal 
height/weight (and therefore BMI) and confounding factors including smoking status 
and alcohol intake at the time of delivery was also incomplete. No significant 
differences were found in the proportion of diabetic case and control mothers (p = 
xv 
 
 
 
0.6305). The recorded number of diabetic mothers was low in both groups (4/138 
and 13/564 respectively). No significant differences were found in mean maternal 
glycosylated haemoglobin levels in diabetic mothers (p = 0.368) or weight (p = 
0.418) between the cases and controls.  
Conclusions: Datasets were found to be incomplete, and confounding factors were 
poorly documented. There is no identifiable link between maternal diabetes and 
OFC in babies born to these mothers within the Tayside population. No significant 
differences were identified regarding glycosylated haemoglobin levels in diabetic 
mothers or weight between case and control mothers. Larger and wide-reaching 
studies are required to overcome the limitations of a relatively small population 
sample. Datasets of maternal information must be complete and confounding 
factors fully documented to allow studies to be accurately performed.
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CHAPTER ONE: INTRODUCTION 
 
Orofacial clefts (OFC) are among the most common birth defects worldwide, with an 
estimated prevalence of around 1 in 700 live births (1). For those individuals born 
with OFC, it will have a profound effect on their health and wellbeing and requires 
complex and lengthy treatment strategies. 
 
Although much research has been carried out focussing on potential genetic and 
environmental causes of OFC, the aetiology of most cases remains unclear. The 
outcome of research studies must be to identity aetiological factors and thus inform 
preventative strategies for future generations (2). 
 
Several recent studies have identified possible links between maternal diabetes and 
maternal obesity and the occurrence of OFC in offspring (3,4). These were 
conducted within a population in the USA. 
 
It is therefore of interest to investigate the possibility of such a link within our own 
population. This will inform both the need for further wider-ranging studies and 
possible protective actions such as screening and pregnancy planning. 
 
The larger and more wide-ranging the evidence base underpinning the aetiological 
factors leading to OFC, the greater the potential to develop such preventive 
strategies. 
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CHAPTER TWO: BACKGROUND AND LITERATURE REVIEW 
 
2.1 Orofacial clefting: Embryology, pathogenesis and aetiology 
 
During embryonic development, any disruption in the fusion of tissues forming the 
lip and palate can result in clefting. The associated anomaly can manifest as either 
cleft lip with or without cleft palate or as isolated cleft palate. 
 
In order to build a clear picture of the pathogenesis of orofacial clefting it is 
important to develop an understanding of the normal embryological development of 
the lip and palate. 
 
2.1.1 Development of the face 
 
Neural crest cells originating in the neuroectoderm migrate vertically and go on to 
form the facial skeleton and many further structures in this area. These cells are of 
vital importance in the development of the craniofacial structures and present a 
vulnerable target during the migration process. 
 
Development of the human face commences during the fourth week in utero when 
migrating neural crest cells join with core mesoderm and the epithelial cover to form 
the facial primordial (5). The primitive mouth is called the stomodeum. 
 
The stomodeum is surrounded by the five facial prominences, consisting mainly of 
neural crest cell derived mesenchyme and formed from the first pharyngeal arch. 
This occurs by the end of the fourth week. These swellings are comprised of the 
frontonasal prominences (upper border of stomodeum), paired maxillary 
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prominences (lateral to stomodeum) and paired mandibular prominences (caudal to 
stomodeum). By five weeks in utero the nasal placodes are formed to either side of 
the frontonasal prominence by local thickening of the surface epithelium (figure 1) 
(6). 
 
 
 
 
 
 
 
Figure 1: Frontal view of an embryo at 4.5 weeks, adapted from (Sadler, 2006) 
 
The primitive nasal cavities appear during the fifth week as the nasal placodes 
invaginate into underlying mesenchyme, thus the nasal pits are formed. The ridges 
of tissue surrounding each pit form from proliferating mesenchyme of the 
frontonasal processes and are known as the nasal prominences. The lateral nasal 
prominences situated on the outer edge of each nasal pit and medial nasal 
prominences on the inner edge. 
 
As the nasal pits continue to proliferate and submerge, they are held separate to the 
stomodeum by the oronasal membrane until its regression at the end of the fifth 
week (figure 2). 
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Figure 2: Frontal view of the developing embryo during the A. fifth week B. 
sixth week in utero, adapted from (Sadler, 2006) 
 
 
In weeks six and seven the lower lip and mandible form following the merging of the 
mandibular prominences across the midline. The maxillary prominences continue to 
grow towards the medial nasal processes causing their compression towards the 
midline. Loss of the cleft between the medial nasal processes and the maxillary 
prominence occurs as they fuse together (figure 3). 
 
 
 
 
 
 
 
 
Figure 3: Frontal view of 7-week embryo. Maxillary prominences have fused 
with the medial nasal prominences. B. 10-week embryo, adapted from (Sadler, 
2006) 
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Some debate exists regarding the formation of the upper lip and primary palate. 
Because the upper lip is innervated by the trigeminal nerve, some believe it must 
form entirely from the maxillary processes which ‘overgrow’ the medial nasal 
processes. The nerve supply would come from the ophthalmic nerve if formation 
had arisen from the frontonasal process (7). Others believe that the maxillary 
processes do not overgrow the medial nasal processes; rather a part of the 
frontonasal process persists to form the philtrum of upper lip. However this does not 
explain the innervations of the upper lip by the trigeminal nerve (8). 
 
The fusion of the maxillary processes with the medial nasal processes forms a 
structure called the ‘intermaxillary segment’. Any teratogenic agent or disruption of 
growth may influence this vulnerable period of cell division, resulting in failure of 
fusion and the formation of a cleft of the lip and/or alveolus. The intermaxillary 
segment is composed of the labial component, the maxillary component and the 
palatal component, which goes on to form the primary palate. 
 
2.1.2 Development of the secondary palate 
 
The secondary palate begins to form during the sixth week in utero. The lateral 
palatine shelves form as outgrowths from the internal aspect of the maxillary 
processes. The nasal septum separates the nasal cavities and a secondary nasal 
septum continues to grow downwards separating the oronasal cavity.  
 
The lateral palatine shelves grow downwards vertically, lateral to the tongue; which 
is the dominant structure in the oronasal cavity (figure 4). 
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Figure 4: 6-week-old embryo in section (A). The palatine shelves are in the 
vertical position on each side of the tongue (B). This shows clefting between 
the primary triangular palate and the palatine shelves, which at this stage are 
still vertical, (adapted from Sadler 2006) 
 
 
During the seventh week, the palatine shelves rise into a horizontal position above 
the tongue. The tongue musculature gains the ability to contract, becomes 
depressed and moves downwards. The lateral palatine shelves become turgid, 
elevate and then fuse to form the secondary palate. Formation of the secondary 
palate can only come about if a series of events occur without complication. The 
head elevates upwards away from the developing chest, the volume of the 
stomodeum increases and as previously mentioned the tongue drops in position 
(figure 5) (8). 
 
 
 
 
 
 
 
 
 
Figure 5: Elevation of the lateral palatal shelves in a 7.5-week embryo, 
adapted from (Sadler, 2004) 
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The lateral palatine shelves fuse not only with each other, but also with the primary 
palate, with the incisive foramen demarcating the point of fusion. This union acts to 
separate the oral and nasal cavities and enables the simultaneous functions of 
respiration and mastication. The nasal septum continues downwards growth to fuse 
with the newly formed palate (figure 6). 
 
 
 
 
 
 
 
 
Figure 6: Fusion of the palatine shelves and the nasal septum in a 10-week 
embryo, adapted from (Sadler, 2006) 
 
During approximation of the palatal shelves, the medial edge epithelium forms a 
midline epithelial seam which rapidly degenerates, establishing continuous 
mesenchyme across the midline. This occurs through a process of cell death, 
migration and transformation (7). Fusion of the secondary palate is normally 
complete by the twelfth week in utero (9), however as horizontal positioning of the 
palatal shelves occurs later in the female embryo, there is an extended period 
during which the open palatal shelves may be susceptible to teratogenic influences 
and therefore a possible correlation with the greater incidence of isolated cleft 
palate in females (10). 
 
During the period of palatal shelf elevation there is almost no increase in head width 
while growth in head height continues (11) and therefore the expanding palatal 
shelves are able to grow above the tongue and fuse. However, if palatal shelf 
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elevation is delayed until the pattern of facial growth takes a horizontal direction 
there may be a failure of palatal shelf contact, and subsequently a failure of fusion. 
 
Much existing knowledge of the development of the secondary palate comes from 
studies of mice due to the similar morphological chronology to humans (12). 
Regulation of palatal shelf initiation and growth is believed to involve complex 
signalling cascades entailing transcription factors, growth factors and their 
receptors, including Osr2, Lhx8, Msx1, Fgf10, Fgfr2b, Tgfb2 and Tgfbr2 (13). Palatal 
growth is regulated by signalling between the palatal epithelium and mesenchyme, 
involving fibroblast growth factor 10 (FGF10) and the receptor FGFR2b found on the 
palatal epithelium. Failure of this communication due to loss of function of signalling 
factors leads to reduced mesenchymal proliferation and a rise in apoptosis. This 
subsequently causes a shortening of the palatal shelves, leaving them unable to 
fuse. 
 
Sonic hedgehog (SHH) expression in the palatal shelves is vital and any loss of 
SHH function can lead to clefting of the palate (14). Maintenance of SHH expression 
is related to activation of FGFR2b by FGF10, further highlighting their importance in 
palatal development. Growth of the palatal shelves is stimulated by SHH (15). 
Furthermore, a loss of function mutation in the gene MSX1 has been identified in 
patients affected by cleft lip and palate (16). 
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2.1.3 Elevation of the palatal shelves 
 
There have been many theories proposed to explain the mechanism of palatal shelf 
elevation and it is still not wholly understood. 
The most plausible explanation is that of an intrinsic force generated within the 
palatal shelves themselves. When this force reaches a threshold exceeding that of 
its resistance (i.e. from the tongue), elevation of the palatal shelves can occur (7). 
Shelf elevating force appears to be due to a regional accumulation of 
glucosaminoglycans, mainly hyaluronic acid. This highly electrostatically charged 
molecule can bind up to ten times its own weight of water. Epidermal growth factor 
stimulates the synthesis of hyaluronic acid by palatal mesenchymal cells, which 
swell to produce an elevating force. Differential proliferation and alignment of the 
mesenchymal cells may add further elevating force and act to influence the direction 
of elevation (7)(17). 
 
The control of palatal shelf adhesion is vital in ensuring the palatal shelves rise and 
do not adhere to the wrong structures. When the shelves are vertical and in close 
proximity to other structures they are ‘adhesion incompetent’, however once 
positioned horizontally above the tongue they are able to adhere to one another and 
thereby prevent clefting. The membrane bound signalling molecule JAG2 and 
interferon regulating factor 6 (IRF6) have been found to be highly influential in this 
process (12,18,19). 
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2.1.4 Fusion of the palatal shelves 
 
Once elevated, the lateral palatal shelves contact each other and also the primary 
palate and nasal septum. The epithelial cells of the medial edges adhere due to a 
sticky glycoprotein coat. These become the central cells of the epithelial seam (7). 
 
Fusion of the palatal shelves appears to be stimulated by cell-adhesion molecules, 
desmosomal components and growth factors such as transforming growth factor α 
(TGFα) and epidermal growth factor receptor (EGFR) plus those in the transforming 
growth factor β family such as TGFβ3 (12). TGFβ3 may play a vital role in palatal 
fusion as it is expressed in the medial edge epithelium prior to and during fusion 
(20). 
 
Once the medial epithelial seam has formed following rapid assembly of 
desmosomal components, there must then be degeneration of the seam to provide 
continuity of mesenchyme across the midline. It would appear that programmed cell 
death (apoptosis) plays a key role in seam degeneration and dead, dying cells and 
those primed for cell destruction have been identified in the disintegrating medial 
epithelial seam (21). There has been much debate regarding the possibility of 
epithelial-mesenchymal transformation, however evidence supports a theory of 
epithelial cell migration not transformation (22). 
 
Following these events there is differentiation of the tissue on the oral and nasal 
aspects of the palate. Within the fused palatal shelves intramembranous ossification 
commences, developing the future hard palate. 
 
 
 
11 
 
 
 
2.1.5 Formation of cleft palate 
 
Any disturbances during the phase of palate development can lead to the formation 
of cleft palate: 
 Defects in palatal shelf growth 
 Delayed or failed shelf elevation 
 Defective shelf fusion 
 Failure of medial edge cell death 
 Post fusion rupture 
 Failure of mesenchymal consolidation and differentiation (9) 
 
If there is a disruption in the formation of both the primary and secondary palate, 
cleft palate may be associated with clefting of the lip and alveolus. Cleft lip and 
palate can also each arise in isolation and have differing embryological origin (23).  
 
Clearly, the time period during which the lip and palate is developing involves a 
complex series of events, and any influence from disruptive factors may lead to 
significant anomalies such as cleft lip and palate. 
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2.1.6 Environmental aetiology of OFC 
 
The findings from epidemiological and experimental studies of OFC implicate 
numerous environmental factors in the development of clefts of the lip and/or palate: 
 Maternal exposure to tobacco smoke/ maternal smoking 
 Maternal alcohol intake 
 Nutritional deficiency 
 Drug intake including anticonvulsants and steroids 
 Maternal systemic illness, elevated maternal blood glucose and obesity 
 
 
Smoking 
 
Maternal smoking during the first trimester of pregnancy has been linked with 
increased risk of a baby being born with CL/P and isolated CP (24,25). A meta-
analysis of 24 studies found ‘consistent, moderate and statistically significant 
associations between both CL/P and CP and maternal smoking’ (26). Mothers who 
smoked during pregnancy had a 1.3-fold risk of having a baby with CL/P and a 1.2-
fold risk of CP alone. A case-control study in the UK by the same author found a 
‘small but statistically significant’ link between maternal smoking during the first 
trimester of pregnancy and risk of OFC (27). Maternal exposure to passive smoking 
may not be well reported, and consequently not assessed in many studies, 
therefore the link between exposure to smoke and OFC may be underestimated 
(12). 
 
 
 
13 
 
 
 
Alcohol 
 
Currently, any link between maternal alcohol intake and non-syndromic oral clefting 
is unclear. Its assessment in previous studies has proven difficult due to several 
factors. It may be problematic to quantify ‘alcohol consumption’ as reported by 
individuals. The confounding effects of other environmental factors such as 
smoking, nutrition and drug use must be considered, and alcohol may also interact 
with and modify the effects of these other environmental factors. Positive 
associations between maternal alcohol consumption and OFC have been found in 
some studies (28-30), but not in others such as Romitti et al in 2007 (31), however 
the results of the former may have been influenced by confounding factors. 
 
Nutrition 
 
A possible link between maternal nutrition and OFC has been identified through 
observational studies, however accurate assessment of nutritional status can prove 
problematic, particularly in poorer populations where the highest rates of OFC are 
seen (12). 
 A meta-analysis by Johnson and Little (2008) found 25% reduction in births 
affected by OFC when the mothers had taken multivitamin supplements (32). 
However these findings may be influenced by confounding factors such as a 
heightened awareness of health and positive healthy behaviours in these mothers. 
Small sample sizes in previous studies may also skew results. 
 
Whether or not dietary intake of folic acid offers protection from OFC remains 
uncertain, despite the results of case-control studies of maternal dietary folate 
uptake, multivitamin supplements containing folic acid and red cell plasma folate 
levels (12). 
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Drug therapy 
 
Several studies have identified a link between anticonvulsant drugs taken to control 
maternal epilepsy, including diazepam, phenytion and phenobarbital and OFC (33-
35). The use of corticosteroids during pregnancy has also been associated with 
OFC (36), as have analgesic and antipyretic medications (37). 
 
Maternal diabetes and obesity 
 
The possible associations between OFC and elevated maternal blood glucose, and 
maternal diabetes and obesity form the focus of this study and will therefore be 
discussed at length further in this review. 
 
Other risk factors 
 
Other factors found to have a positive association with OFC include environmental 
pollution, e.g. domestic due to poor ventilation during cooking and heating, 
consumption of pickled vegetables more than six times per week and a history of 
fever and cold (37). Viral infection may be relevant in development of OFC as 
interferon regulatory transcription factors are activated following viral infection, and 
IRF6 has been seen to be associated with clefting (38). 
 
Summary 
 
Numerous studies have implicated a wide range of possible environmental factors in 
the aetiology of cleft lip and palate. It has been difficult to separate these factors and 
ascertain their individual effects. Additionally they may act to modify to other factors. 
15 
 
 
 
Future studies may aim to separate these factors where possible to analyse theit 
individual effects. 
 
 
2.2 Genetics and OFC 
 
Whether identified as CL/P or isolated CP, orofacial clefting can also be classified 
as non-syndromic OFC, clefts associated with chromosomal and monogenic 
syndromes, and clefts found in infants with multiple congenital anomalies (MCA) 
(39-41). Around 30% of CL/P and 50% of CP patients have some other congenital 
anomaly or an associated syndrome (42). If a cleft occurs in an individual who has 
other consistently related features, it can be termed as syndromic, with CL/P found 
in over 200 genetic syndromes and CP in over 400 (43).  
 
Genetic factors are thought to play an important role in the aetiology of OFC, with 
20% of patients showing a positive family history (44). Recent advances in 
quantitative and molecular analysis have made association and linkage studies of 
the aetiology of OFC possible (45). 
 
Several previous studies have added to our knowledge of the genetic components 
of OFC development. The work of Fogh-Andersen first provided population-based 
evidence of a strong genetic component in OFC (46). However the results of 
historical studies may have been affected by the aggregation of samples from 
differing geographical, racial or ethnic origins, or by small family sample groups 
(44). 
 
It can be agreed that orofacial clefting has a multifactorial aetiology with genetic and 
environmental influencing factors. Where specific genetic disorders are excluded, 
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there remains a greater recurrence risk to siblings of those affected than can be 
predicted by aggregation of familial risks (47). There are increased concordance 
rates of OFC for monozygotic twins over dizygotic twins (48), and epidemiological 
studies consistently reveal increased rates of clefting and predominance of left 
sided clefting in males, further indicating a key role for genetic inheritance in OFC 
(49). Clefts of the primary palate that involve the lip and/or palate may also feature a 
different underlying mechanism to those of the secondary palate (50). 
 
Studies utilising the technique of segregation analysis have thus far yielded a 
relatively small number of genes to be implicated with OFC, with a study by 
Fitzpatrick and Farrell in the West of Scotland identifying three or four major loci 
(51) and another study in England revealing two to fourteen loci (52). 
 
Research focussing on the causes of OFC must take into account the complex and 
multifactorial aetiological picture, involving the identification of individual genes and 
the effect of gene-environment interactions. Several genes that play an important 
and interactive role in up to 20% of all clefts have recently been identified (42), 
however it is apparent that further causative genes remain unidentified. 
 
Existing studies have used association and linkage analysis to investigate the 
influence of candidate genes in the aetiology of OFC; however a lack of consistency 
in results may be attributed to small sample groups or genetic heterogeneity 
(12,42). The difficulties in studying the genetics and associated environmental 
interactions have been further reflected in inconsistent results from population-
based association studies. IRF6 had been the only gene to be consistently linked 
with non-syndromic CL(P) until 2009 (2). Genome-wide association studies (GWAS) 
may now provide an exciting opportunity to expand our knowledge of the genetic 
causes of OFC (53-56) 
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The interaction of aforementioned environmental risk factors with certain genes, and 
the variation with these genes, has an impact on the risk for OFC. There is a 
possibility that a developing foetus has a low genetic risk of developing OFC, 
however this risk is increased due to the environmental factors to which the mother 
is exposed and to her metabolism and inherent ability to detoxify these exposures 
(42). 
 
Following the results of studies of monozygotic twins, finding levels of concordance 
for OFC below 100%, the hypothesis that OFC is not caused by genetic factors 
alone is further supported (50). Genetic and environmental factors may act in 
isolation or in synergy, therefore the study of gene-environment interactions (GEIs) 
can greatly add to our understanding of the aetiopathogenesis of OFC. Finding from 
such studies can provide guidance for global public health strategies, as it is much 
less contentious and theoretically possible to influence an individual’s environment 
rather than their genetic profile. Strategies to alter environmental risk factors may be 
especially significant where those with a susceptible genetic profile can be 
identified. Although several potentially important GEIs have been investigated, 
currently the results are uncertain and have not been consistently replicated (12). 
 
 
2.3 Epidemiology of OFC 
 
Orofacial clefts are among the most common birth defects seen on a worldwide 
level, with incidence varying widely between different populations. Although the 
variation in geographical distribution of OFC due to differing birth prevalence has 
been widely recognised, the larger picture is not complete due to a lack of 
consistency and completeness in the recording of births and deficiencies in birth 
defect detection frameworks. There are also issues with source population of births 
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recorded, method of ascertaining data, time frame, sampling fluctuation and 
differences in inclusion and exclusion criteria. Some areas of the world are 
represented by very little information regarding the frequency of OFC, including 
parts of Eastern Europe, Africa and Asia (57). 
 
The available data from a comprehensive overview of OFC epidemiology (58) 
indicates that OFC occurs in around 1 in 700 live births, but with significant ethnic 
and geographic variation (1). The WHO International Collaborative Research on 
Craniofacial Anomalies project aims to address the deficiencies in birth defect 
surveillance, particularly in the developing world (12). 
 
2.3.1 Global studies 
 
Worldwide, rates of detection of isolated CP may differ to those of CL/P due to the 
readily identifiable external phenotypic appearance of cleft lip. There is considerable 
variation in the incidence of CLP between different populations globally. Latin 
America, China and Japan have high rates of CL/P, while rates are low in Southern 
Europe, South Africa and Israel. Rates of isolated CP are elevated in Northern 
Europe, particularly Finland, and Canada while low rates of incidence are found in 
Latin America and South Africa (12).  
 
The International Perinatal Database of Typical Orofacial Clefts (IPDTOC) was 
established in 2003 and collates data on CL/P and isolated CP from the European 
Surveillance Systems of Congenital Anomalies (EUROCAT) in Europe, the National 
Birth Defects Prevention Network (NBDPN) in the USA and the International 
Clearinghouse for Birth Defects Surveillance and Research (ICBDSR) worldwide. 
The 2011 IPDTOC working group publication provided data from 54 registries in 30 
countries, covering at least one complete year from 2000-2005. This comprised 
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over 7.5 million births. 7704 cases of CL/P were identified, including 237 still births, 
301 terminations of pregnancy (TOPs) and 25 with unknown pregnancy outcome. 
This gave an ‘overall’ prevalence of 9.92 per 10,000 for CL/P. The prevalence of CL 
was 3.28 per 10,000 and that of CLP was 6.64 per 10,000. 
While 12 registries had a prevalence of CL/P statistically higher than the overall 
estimate of 9.92 per 10,000, 13 registries had a lower rate. The areas of highest 
prevalence were in Germany, Japan and Denmark, while the lowest rates were in 
Italy, South Africa and the USA. 
 
Data may have been skewed due to registries that did not record TOPs. The areas 
reporting the highest rates of TOPs were the British Isles (16.7%), South-
Mediterranean Europe (15.7%) and Western Europe (11.7%). Most TOPs were 
registered in multiple malformed cases, while they were rare in isolated cases of 
CL/P (59). 
 
There is considerable variation in the prevalence of OFC in Europe. Prevalence of 
CL/P ranges from 3.4-22.9 per 10,000 births, while that of isolated CP showing 
greater variation with a range of 1.3-25.3 per 10,000 (58). These differences 
between European countries are believed to be true differences, and therefore not 
due to variable ascertainment rates, due to the consistent procedures involved with 
data collection for the EUROCAT registry (1). The European birth prevalence of cleft 
lip and palate is shown in figure 7. 
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Figure 7: European birth prevalence per 1000 live births of non-syndromic 
cleft lip and palate. (A) CL/P. (B) Isolated CP. (from http://www.eurocran.org/) 
 
 
 
Studies of immigrant groups to the USA from China and Japan suggest that the 
rates of CLP in these groups are more closely related to their area of origin 
compared to the region to which they have migrated (60,61). This indicates a 
genetic component which may interact with environmental factors in the aetiology of 
OFC. 
 
Prevalence of CL(P) in Europe has been seen to positively correlate with South to 
North geographic location (59). There is speculation that this may be influenced by 
differing facial shape (62) and to levels of exposure to the sun with regards to 
vitamin D production. 
 
2.3.2 Sex distribution 
 
The differences in prevalence of OFC between males and females are well 
documented. The male sex has a tendency to CL/P, with a ratio of 2:1 reported in 
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white ethnic groups (49), while a study of a Scottish population found a 1.8:1 ratio 
(63). Females have a predilection towards isolated CP (39), this may be at least in 
part to the later elevation of the palatal shelves in the female embryo which provides 
a greater timeframe in which disruptive influences may act (9). 
 
2.3.3 Cleft types and associated malformations 
 
CL/P and isolated CP are often found in association with other congenital 
anomalies. This appears to be the case more frequently when considering isolated 
cleft palate (49). It may be the case that the presence of more obvious defects 
affecting other areas of the body may lead to detection of a cleft palate which may 
have otherwise remained undiagnosed.  
 
A study of nearly 4000 cases of isolated CP in Europe found that 55% were 
isolated, 18% were associated with other anomalies and 27% were a feature of a 
recognised syndrome (64). This study also found that in over 5000 cases of CL/P 
71% were isolated, while 29% were associated with other anomalies. 
 
It has been suggested that incidence of OFC should be reported separately for live 
births, still births and terminations of pregnancy, and also divided from clefts with 
associated anomalies. This is because TOPs with CL(P) have more severe 
associated malformations, and the chance of OFC having developed in cases of still 
birth and TOPs is around three times that seen in live births. Cleft cases found with 
associated anomalies feature a different epidemiological distribution to non-
syndromic cases of OFC (1). 
 
It has been noted that where the prevalence of CL(P) is highest globally, the ratio of 
CLP to CL is also highest. This was first described by Mossey and Little (2002) and 
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further reinforced by the IPDTOC report. This supports a multifactorial model, which 
predicts that as the overall level of CL(P) in a population increases there is a greater 
genetic liability within that gene pool, leading to greater rates of CLP as opposed to 
CL (1,59). 
 
Some evidence suggests an increased rate of additional malformations where 
bilateral clefts exist in comparison to unilateral clefts (65). The most commonly 
identified anomalies occurring in combination with OFC are congenital heart 
disorders and limb/vertebral column defects, although the genetic input remains 
unknown (1). 
 
2.3.4 Future work 
 
In order to develop strategies for future primary prevention of OFC, aetiological 
research must be supported by investigation into associations and trends within and 
between populations by epidemiological study. As it is already widely recognised 
that non-syndromic OFC has a complex polygenic multifactorial basis with ethnic, 
racial and geographical variation, investigation of these factors at a population level 
is vital in building the bigger picture of OFC aetiology and supporting work towards 
ascertaining methods for possible future prevention. 
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2.4 The impact of OFC 
 
When a baby is born with CL(P), there will follow many questions, issues and 
consequences for the individual, their family and those within their social sphere. 
Many of these issues can be life-long, involve difficulties, expense and 
stigmatisation, particularly the social isolation found in some parts of the world. 
 
Parents of a child born with OFC often have feelings of guilt, isolation, depression 
and disbelief. The immediate effect on parent/child bonding may have important 
consequences. 
 
2.4.1 Feeding 
 
The communication between the oral and nasal cavities in babies born with cleft 
palate poses a problem for feeding. Jones (1988) reported significant feeding 
problems and lower mean weight gain in a quarter of babies with non-syndromic 
OFC studied (66). Another study found that one third of newborns had problems 
with feeding; however this effect did diminish over time (67). Both studies noted that 
those individuals with the greatest experience of feeding difficulty had CP or CLP, 
while those CL had the least difficulty. 
 
Britton et al (2011) found that in the Scottish population, 54% of children with OFC 
were breast-fed at birth, in comparison to 70% of non-cleft babies. Those with CL 
were more likely to be breast-fed than those with CP (68). 
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2.4.2 Hearing 
 
Deficient middle ear drainage due to Eustachian tube dysfunction leads to hearing 
problems in individuals born with OFC affecting the posterior palate. A lack of 
muscular activity in the tensor veli palatine muscles of the soft palate causes the 
defective drainage, which may lead to recurrent infections of the middle ear and 
eventual rupture of the ear drum. Ventilation tubes (grommets) are routinely placed 
to prevent these problems arising. In a study of patients with unrepaired palatal 
clefts, up to 60% suffered from hearing impairment (69). 
 
2.4.3 Speech 
 
Defective speech may occur due to velopharyngeal insufficiency and can also be 
affected by poor hearing. Velopharyngeal insufficiency arises when the soft palate is 
unable to contact the posterior pharynx and close off the nasal airway. Although 
surgery improves speech in the majority of individuals with OFC, around 25% fail to 
develop adequate speech (70). Health Related Quality of Life (HRQoL) is 
significantly impaired in those with severe speech problems, and therefore this 
consequence of OFC may pose major issues for the individual and those around 
them (71). 
 
2.4.4 Dental anomalies associated with OFC 
 
The dental anomalies found in association with CLP include delayed dental 
development and eruption, impactions, hypodontia, enamel defects and anomalies 
of tooth size and shape. 
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Tortura et al (2008) found 48% of patients with UCLP to have a missing lateral 
incisor on the cleft side, with only 6% on the non-cleft side. They also reported an 
increased incidence of supernumerary or supplemental lateral incisors in these 
individuals (72). A twenty-fold increase in the risk of maxillary canine impaction has 
also been described (73). Orthodontic input is required from the early stages of an 
affected child’s life and will continue for many years. 
 
Scarring of the maxillary tissues following palate repair may cause maxillary arch 
restriction and present clinically as an anterior and/or posterior crossbite (74) . A 
combined orthodontic/orthognathic approach may be undertaken in order to correct 
the skeletal anomaly and associated malocclusion. This of course adds 
considerably to the burden of care. 
 
2.4.5 Summary 
 
There are significant challenges and costs which affect the life of a child born with 
OFC and also those around them and who care for them. Although much work has 
focussed on the management and assistance of those affected by OFC, the ultimate 
objective must be primary prevention. 
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2.5 Health inequalities in orofacial cleft care 
 
There is considerable variation in rates of mortality and levels of access to care 
between, and also within, different countries worldwide. There is also variation in the 
quality of care and many children may be left affected by residual deformity and 
disability for life. In some cases clefts may remain unrepaired into adulthood. This is 
a significant problem in India, where 76% of patients with un-operated cleft palate 
suffer from mild to moderate conductive deafness (75) and very few achieve normal 
speech (76). Because of limited access to medical and surgical care in India, there 
is a perception that OFC is a life-threatening deformity. There may be reduced 
awareness that surgical repair is possible. Subsequently, many infants with OFC 
succumb to infection and malnutrition. 
 
Surveillance systems for birth defects are generally deficient in India, with stark 
differences between rural and hospital based studies of prevalence. Rates of OFC 
prevalence may be found to be low in comparison to other populations, but this may 
be attributed to high rates of infant mortality. It is therefore important to achieve a 
precise estimate of the prevalence and distribution of OFC in the Indian population 
in order to target public health measures and reduce morbidity and mortality. 
 
One indication of access to treatment is the age range of individuals with CLP 
receiving primary cleft surgery. It can be seen that in richer areas with better access 
to early surgery and treatment there is a much higher percentage of successful 
outcome (see figure 8). This highlights health inequalities between racial, ethnic and 
geographical groups. 
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Figure 8: The upper curve shows long-term survival of patients with orofacial 
clefts repaired in infancy: there is modestly increased all-cause mortality at all 
ages (Christensen et al 2004). The lower curve shows estimated survival with 
unoperated oro-facial clefts in India, based on Smile Train data. Adapted from 
(1) 
 
 
Of course health inequalities also exist in our own population and it is known that 
factors such as social class and negative health behaviours are related to other 
chronic health problems such as diabetes and obesity. This is known as the 
‘common risk factor’ approach and was outlined in the Marmot Health Inequalities 
Review (2008) (http://www.ucl.ac.uk/gheg/marmotreview/). 
 
Irregularities of care and service organisation are global issues, and therefore the 
WHO has stressed the requirement for strategies to improve clinical care through 
international collaboration between cooperatives. Outcome measures such as 
psychological and quality of life statuses require urgent attention. 
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2.6 Cleft registers and UK studies 
 
Clinical cleft registries provide vital sources of data which can be used to inform 
important research, including epidemiological and genetic studies. The importance 
of registries in providing the framework for a collaborative network that can inform 
descriptive epidemiology, raise public awareness of health issues and support 
education, training and research has been highlighted by the WHO (58). 
 
An advantage of using databases for epidemiological research is that populations 
can be studied in a relatively short period of time; however sample size should be 
adequate, and where the birth rate of the characteristic being studied is less than 
2000 per year, at least ten years of data should be analysed (58). 
 
Registries are either hospital based or population based, with the disadvantage of 
hospital based registries having potentially skewed data due to movement within 
regions at attend hospitals elsewhere and limitations of hospital access to those 
lacking in resources and living in deprived areas.  
 
The importance of consistent protocols within the structure of population registries 
has been stressed by the WHO. Core areas to be input in cleft registries include 
differentiation between syndromic and non-syndromic OFC. The European Science 
Foundation (ESF) Common Core Protocols Project – Minimum Data Sets has 
proposed the recording of demographic information such as lifestyle factors and any 
existing pre-natal diagnoses, and the usage of a coding system for OFC that is 
internationally recognised and reproducible. 
 
The International Database for Craniofacial Anomalies (IDCFA) was set up under 
the guidance of the WHO in order to collate data from the existing 62 registries that 
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are amenable to use for research and collects information on around 2 million births 
per year (77). 
 
One of the greatest challenges to be overcome when aiming to build a global 
database of craniofacial anomalies is the collection of data from poor countries 
where standardisation of healthcare and data collection may be deficient. There 
may also be difficulties in the coding of anomalies, method of data collection and 
omissions due to terminations of pregnancy. 
 
Within the UK, various studies based on databases and registries have reported on 
rates of birth prevalence of CL(P) (Table 3). 
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Table 1: Birth prevalence of CL(P) in the UK, adapted from (78) 
 
 
 
 
 
 
 
 
 
 
  Authors 
 
Source 
 
No. 
of 
clefts 
 
  Region 
 
Time 
span 
 
No. of 
births 
 
Birth prevalence (per 
1000 live births) 
 
CL(P) 
 
  CP 
All 
clefts 
 
McMahon and 
Mckeown, 1953 
 
Clinical 
records 
 
285 
 
Birmingham 
 
1940-50 
 
218,693 
   
1.3 
 
Knox and 
Braithwaite,1962 
 
Hospital 
records 
 
574 
 
Northumberland 
 
1949-58 
 
404,124 
 
0.95 
 
0.47 
 
1.42 
 
Leck 1969 
 
Registry 
 
353 
 
Liverpool 
 
1950-59 
 
186,046 
   
1.9 
 
Owens et al, 
1985 
 
Registry 
 
456 
 
Liverpool 
 
1960-82 
 
325,727 
   
1.4 
 
Leck and 
Lancashire, 
1995 
 
Registry 
 
718 
 
Birmingham 
 
1960-84 
 
432,778 
 
1.04 
 
0.62 
 
1.66 
 
Womersley and 
Stone, 1987 
 
Registry 
 
247 
 
Glasgow 
 
1974-85 
 
158,333 
 
0.75 
 
0.81 
 
1.56 
 
Coupland and 
Coupland, 
1988 
 
Hospital 
activity 
analysis 
 
930 
 
Trent 
 
1973-82 
 
617,940 
   
1.51 
 
Fitzpatrick et al, 
1994 
 
Regional 
database 
 
286 
 
W. Scotland 
 
1980-85 
 
187,321 
 
0.74 
 
0.79 
 
1.53 
 
Gregg et al, 
1994 
 
Regional 
database 
 
398 
 
N. Ireland 
 
1980-90 
 
310,838 
 
0.6 
 
0.68 
 
1.28 
 
Bellis and 
Wohlgemuth.B, 
1999 
 
Regional 
database 
 
503 
 
S.E. Scotland 
and Highlands 
 
1971-90 
 
356,922 
 
0.77 
 
0.63 
 
1.4 
 
Cousley and 
Roberts-Harry, 
2000 
 
Regional 
database 
 
132 
 
Yorkshire 
 
1994-95 
 
82,265 
 
0.88 
 
0.73 
 
1.6 
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2.6.1 CLEFTSiS  
 
The National Managed Clinical Network for Cleft Service in Scotland (CLEFTSiS) 
has been collating data on OFC in Scotland since 1989. Prior to the year 2000, 
demographic data on OFC in Scotland was held by the Scottish Association for Cleft 
Lip and Palate (SCALP); however the outcomes of the Clinical Standards Advisory 
Group (CSAG) report of cleft services in the UK lead to the National Services 
Division (NSD) commissioning the CLEFTSiS network to succeed into this role. 
 
     
                                    Figure 9: CLEFTSiS logo 
 
 
The CLEFTSiS mission statement reads: "Every patient with a cleft lip, cleft palate 
or cleft lip and palate is offered specialist cleft care from diagnosis to adulthood. We 
work with the family to offer the right care, in the right place at the right time to 
produce the best possible outcome for the patient" (http://www.cleftsis.scot.nhs.uk/). 
 
When a child is born with CL(P) in Scotland, the CLEFTSiS team is notified within 
24 hours. A visiting clinician will then complete a form (Appendix I) that records 
details regarding the patient and their parents. This is subsequently entered into the 
EPR with a completed consent form (Appendix II), which will soon be replaced with 
an information leaflet. 
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The aim of CLEFTSiS is to ensure interdisciplinary care for those affected by OFC, 
including access to care that meets agreed clinical standards, the planning of future 
care, the provision of clinical governance frameworks and to maintain the electronic 
patient record (EPR). The CLEFTSiS EPR records information regarding all live 
births with OFC in Scotland and its purpose is to maintain a record of all clinical 
activities and interactions for each patient in order to allow joined-up care between 
all the specialties involved. The records held include study models, clinical 
photographs, radiographs and details of audiology and speech and language 
investigations and assessments, collected according to agreed protocols. 
 
2.7 Record linkage 
 
H.L.Dunn of the United States national Bureau of Statistics introduced the term 
‘Record Linkage’ in 1946: “Each person in the world creates a Book of Life. This 
Book starts with birth and ends with death. Record linkage is the name of the 
process of assembling the pages of this book into a volume” (79). 
 
Record linkage studies are those which bring together information on the same 
individual from two or more independent sources of data (80). The advent of 
computerised record linkage has allowed for increased speed, consistency and 
reliability of results, and the ability to process large volumes of data. Datasets can 
be anonymised to exclude any patient identifiable information. The simplest form of 
record linkage is known as ‘deterministic linkage’. This involves using a unique 
numerical identifier to test agreement on one or more variables, and was employed 
in this study. 
 
Record linkage may be utilised in a case-control observational study where more 
than one dataset contain information regarding the same individual, and these can 
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be matched to corresponding controls. Ideally, all the datasets being considered 
should undergo quality assessment, as key identifiers may be represented 
differently between sets and make interpretation difficult. Where the data being 
studied has multiple dates of reporting, the most appropriate date must be selected, 
and can prove to be a time-consuming task. 
 
2.8 Conclusions from this section 
 
The aim of this first section of background information has been to highlight the 
complex aetiological basis of OFC and the subsequent range of impacts on the life 
of the affected individual, combined with the intricate framework of care and support 
they require. 
 
There is a great need for further research into the genetic and environmental 
aetiological factors, which may inform future preventative strategies. This research 
must be based upon accurate data, of which important sources include national and 
international databases and registries, and may utilise the potentially valuable tool 
of record linkage. 
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2.9 The Metabolic Syndrome, Diabetes and OFC 
 
2.9.1 The Metabolic Syndrome 
 
The Metabolic Syndrome (MetS) has been defined as ‘the clustering of various 
metabolic risk factors that include abdominal obesity, dyslipidaemia, hypertension 
and hyperglycaemia’ (81) (Figure 10, table 4). It is closely associated with increased 
risk of cardiovascular disease and type 2 diabetes, posing a significant concern for 
public health. 
 
 
Figure 10: The Metabolic Syndrome 
 
 
Pathophysiologically, the MetS appears to be largely due to insulin resistance and 
excess fatty acids (82). Therapeutic intervention is aimed at achieving healthy 
lifestyle changes such as weight loss, healthy eating and physical activity.  
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Table 2: Metabolic Syndrome World-wide Definition, adapted from (83) 
 
CENTRAL OBESITY: 
Men >40 inch waist circumference 
Women >35 inch waist circumference 
Plus any two of the following: 
 
 RAISED FASTING TRIGLYCERIDES: 
≥ 150 mg/dl (1.7 mmol/l) 
or specific treatment for this lipid abnormality 
 
 
 REDUCED HDL-CHOLESTEROL: 
< 40 mg/dl (1.03 mmol/l) in males 
< 50 mg/dl (1.29 mmol/l) in females 
or specific treatment for this lipid abnormality 
 
 RAISED BLOOD PRESSURE: 
Systolic ≥ 130 mmHg 
or Diastolic ≥ 85 mmHg 
or treatment of previously diagnosed hypertension 
 
 RAISED FASTING PLASMA GLUCOSE: 
≥ 100mg/dl (5.6 mmol/l) 
or previously diagnosed type 2 diabetes 
 
 
 
 
 
2.9.2 Diabetes 
 
Diabetes mellitus is one of the most prevalent chronic diseases worldwide, with 
incidence currently increasing; this can be related to changes in lifestyle factors 
such as reduced physical exercise and a global increase in obesity. Type 1 diabetes 
occurs due to autoimmune destruction of the insulin-producing cells of the pancreas 
and is mainly diagnosed in children and young adults. Type 2 diabetes is generally 
diagnosed in adults over 40; however the number of younger people developing the 
disease is rising. In type 2 diabetes, insulin production may be insufficient or there 
may be insulin resistance, which may be related to autoimmunity, single gene 
mutations and obesity. 
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Globally, type 2 diabetes is increasing in all age groups and accounts for over 90% 
of all recorded cases of diabetes (84,85). The prevalence of diabetes increased by 
33% in the USA between 1990-1998 (86). Worldwide estimates of diabetes 
prevalence were 2.8% in 2000 (87), while Shaw et al predict a global prevalence of 
7.7%, or 439 million adults, by the year 2030 using data from 216 countries in the 
United Nations (88). 
 
There are greater numbers of women with diabetes than men, and a worrying 
increase in the prevalence of type 2 diabetes in adolescents (89). Individuals with 
type 2 diabetes also commonly posses other risk factors for cardiovascular disease 
including dyslipidaemia and hypertension. The diagnostic blood glucose levels for 
diabetes are seen in table 3. 
 
Glycosylated haemoglobin (HbA1c) acts as a marker for average plasma glucose 
concentration. It is a form of haemoglobin formed following exposure to plasma 
glucose and reflects average plasma glucose over the previous 8 to 12 weeks. It 
can be performed at any time of the day and does not require any special 
preparation such as fasting. The WHO recommends An HbA1c of 6.5% is as the cut 
point for diagnosing diabetes, however a value of less than 6.5% does not exclude 
diabetes diagnosed using glucose tests. 
 
The use of HbA1c can avoid the problem of day-to-day variability of glucose values, 
and importantly it avoids the need for the person to fast and to have preceding 
dietary preparations. 
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Table 3: Diagnostic blood glucose levels for diabetes (From WHO) 
 
 
2.9.3 Diabetes in Scotland 
 
The Scottish Diabetes Survey (2011) has reported on data collated from the 14 
NHS Boards across Scotland, identifying the current prevalence of diabetes and the 
progress being made in care provision and outcome. Type 1 and type 2 diabetes 
are reported separately. Some of the key findings include: 
 There were 247,278 people with diagnosed diabetes on local diabetes 
registers, which represents 4.7% of the population of Scotland 
 88% (217,514) had type 2 diabetes 
 11.4% had type 1 diabetes 
 0.6% had ‘other’ forms of diabetes 
 Of those patients who had a recorded BMI, 36.6% of those with type 1 and 
31.7% of those with type 2 diabetes were overweight (BMI 25-30), while 
24.5% of those with type 1 and 55.4% of those with type 2 diabetes were 
obese (BMI >30) 
 
Condition 
 
2 hour postprandial 
glucose (mmol/l) 
 
 
Fasting glucose 
(mmol/l) 
 
HbA1c (%) 
 
Normal 
 
 
<7.8 
 
<6.1 
 
<6.0 
 
Impaired fasting 
glycaemia 
 
 
<7.8 
 
 
≥6.1 & <7.0 
 
6.0-6.4 
 
Impaired glucose 
tolerance 
 
 
≥7.8 
 
<7.0 
 
6.0-6.4 
 
Diabetes mellitus 
 
 
≥11.1 
 
≥7.0 
 
≥6.5 
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 Of those patients with a recorded blood glucose level (HbA1c), 22% of those 
with type 1 and 62.1% of those with type 2 diabetes had a result <58 
mmol/mol (7.5%), which is the target level reported in previous surveys 
 25.1% (type 1) and 18.5% (type 2) were current smokers (90) 
 
The results of this survey clearly show that diabetes is a significant and common 
problem for the health of the Scottish population. High levels of obesity must play an 
important role in the development of the current situation with respect to high 
prevalence of type 1 and type 2 diabetes. 
 
 
2.9.4 Gestational diabetes 
 
Gestational diabetes mellitus (GDM) can be defined as ‘glucose intolerance of 
various degrees that is first detected during pregnancy’ or ‘any degree of glucose 
intolerance with onset or first recognition during pregnancy’ (91,92). The White 
classification distinguishes between new-onset GDM (Type A) and pregestational 
(undiagnosed) diabetes (Type B) (93). GDM is diagnosed where insulin resistance 
continues beyond 24-28 weeks of pregnancy. Between 3-10% of pregnancies are 
affected by GDM (101). 
 
In the UK, a diagnosis of GDM is made following a non-challenge blood glucose test 
where the plasma glucose level is found to be higher than 126 mg/dl (7.0 mmol/l) 
after fasting. 
 
Insulin resistance normally increases during pregnancy to a certain extent, and by 
the third trimester these levels may be equivalent to those seen in type 2 diabetes. 
However pregnant women with GDM have greater levels of insulin resistance than 
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normal pregnant women. This may be due to the effects of pregnancy hormones 
such as cortisol and progesterone produced by the placenta and also possibly 
increased maternal adiposity. This raised insulin resistance cannot be compensated 
for by the normal increase in insulin secretion by the pancreatic β cells, as these 
have been found to have defective function (94). 
 
Following delivery, women with GDM have greater insulin resistance than normal 
women, and many (35-60% reported) will progress to the development of diabetes 
over time (95).  
 
The effects of GDM on the developing foetus are still not wholly understood. 
Glucose transporters 1 and 3 (GLUT1 and GLUT3) protein membrane carriers 
facilitate the diffusion of glucose across the placenta and embryonic cell 
membranes during critical periods of embryonic development. In untreated GDM the 
developing foetus is exposed to consistently higher glucose levels than normal. 
Foetal insulin levels rise accordingly and stimulate excessive growth and 
macrosomia. Embryonic cells suffer from increased metabolic load, leading to 
increased formation of reactive oxygen and oxidative stress. This may result in 
impaired embryonic gene expression, followed by apoptosis or disturbed 
organogenesis (96).  Following birth insulin production remains high, and the 
newborn is therefore susceptible to hypoglycaemia. 
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2.9.5 Maternal diabetes and congenital anomalies  
 
A substantial amount of epidemiological research implicates maternal diabetes as a 
highly significant risk factor for birth defects, with both in vivo and in vitro studies 
have identified hyperglycaemia as factor that may induce congenital malformations. 
Maternal obesity and high pre-pregnancy weight are also associated with the risk of 
congenital anomalies (96). 
 
The descriptive study reported by the Confidential Enquiry into Maternal and Child 
Health of pregnant women with type 1 and 2 diabetes in England, Wales and 
Northern Ireland (84) looked at rates of Perinatal mortality, still birth, neonatal 
mortality and congenital anomalies. It found that of a total of 620,830 births in these 
countries in 2002, 2359 were born to women with pregestational type 1 and 2 
diabetes (0.38%). The median pre-pregnancy HbA1c value was 7.9%, and women 
with type 1 diabetes had higher levels of HbA1c throughout pregnancy than those 
with type 2. A higher pre-pregnancy HbA1c level of 8.35% was seen in women who 
had a baby with major congenital malformations. No difference was identified in 
perinatal mortality rates of babies of women with type 1 or type 2 diabetes. 
 
The prevalence of major congenital anomalies was 41.8 per 1000 births, with a 
three-fold increase in anomalies of the circulatory system and neural tube defects. 
Of the reported 2359 babies born to women with diabetes, one (0.042%) had CL(P) 
and three (0.13%) had CP.  
 
The possible link between diabetes and raised maternal blood glucose levels with 
congenital anomalies including OFC has been the subject of numerous previous 
studies. Vallance-Owen et al (1967) studied 34 mothers who had babies with CL(P) 
and found them to have increased insulin resistance related to diabetes (97). 
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Navarette et al (1970) studied 349 women who had babies with congenital 
malformations and found a ‘high and increasing frequency of known diabetes’ over 
0, 12 and 25 years. They hypothesised that there was a definite link between 
maternal glucose metabolic disorder and congenital malformations. None of the 
case mothers had abnormal fasting glucose during their pregnancy with the 
malformation, leading the authors to conclude that “a search for a latent glucose 
metabolic disorder in mothers bearing a malformed baby might make a useful 
contribution to the prevention of human congenital malformations.” (98). 
 
As part of the Atlanta Birth Defects Case-Control Study, Becarra et al looked at 
4929 births with major congenital anomalies and 3029 matched non-malformed 
babies. The relative risk for major congenital anomalies with insulin-dependent 
diabetes was 7.9 compared to infants from non-diabetic mothers. This study may 
have been limited by its retrospective design and an underestimation of diabetes 
orevalence. Diamond (1996) found congenital malformations in 13% of 199 babies 
born to mothers with type1 diabetes, however this did not include CL(P) (99). 
 
Towner et al studied 332 consecutive infants born to mothers with type 2 diabetes 
over a 6 year period. 16.9% had one or more congenital anomaly. Maternal HbA1c 
level (mean 9.5 ± 0.4%) was directly associated with major malformations. Women 
who had a younger age at onset of diabetes were also found to have an increased 
risk (100). This study utilised prospectively collected data and stepwise regression 
analysis. 
 
In a study of mothers with established and gestational diabetes (GDM), Janssen et 
al found that infants born to mothers with established diabetes are more likely to 
have congenital anomalies than infants born to non-diabetic mothers (prevalence 
odds 4.0), however only a slightly higher prevalence of congenital anomalies were 
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found in the babies of mothers with GDM. They recommended screening for 
impaired glucose tolerance (IGT) to identify women with undiagnosed abnormalities 
of glucose metabolism, and are thus at increased risk of delivering an infant with 
malformations (101). Schaefer-Graf et al investigated patterns of congenital 
anomalies in relation to maternal fasting glucose levels in type 2 diabetes and GDM. 
In this study of 3764 pregnancies with GDM and 416 with type 2 diabetes, increased 
hyperglycaemia was found to be positively related to congenital anomalies; however 
they did not compare these cases to a control group (102). 
 
Macintosh et al used data from the Confidential Enquiry into Maternal and Child 
Health (CEMACH 2002-2003) to study rates of congenital anomalies in babies born 
to women with types 1 and 2 diabetes. They reported high rates of malformations, 
although there we no babies with CL(P) and only 2 of 2400 babies had isolated CP 
(103). Farrell et al carried out a prospective study over fifteen years and found that 
women with GDM who were likely to have had pre-existing undiagnosed type 2 
diabetes had the same rate of congenital anomalies in their offspring as women with 
established type 1 or 2 diabetes. While in the remainder of the GDM group, the rate 
did not differ from that seen in non-diabetic mothers. This study may have suffered 
from under-reporting of pre-existing diabetes and a lack of control mothers (104). 
 
Loeken carried out a study using a mouse model and identified excess glucose 
metabolism by the embryo resulting from maternal hyperglycaemia, leading to 
oxidative stress with impaired embryonic gene expression and neural tube defects 
(105). This may not however be directly relatable to these conditions in humans. 
 
Aberg et al carried out a study using the Swedish Medical Birth registry from 1987-
1997. In mothers with pre-existing diabetes the total malformation rate was 9.5% 
and included OFC, while the rate for mothers with GDM was similar to the rate in 
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the general population at 5.7%. They concluded that within the group of mothers 
with GDM there may be a subgroup with an increased risk of diabetic embryopathy, 
which may be due to undiagnosed pre-existing diabetes (106). This study was 
strengthened by the availability of a large birth registry covering over one million 
births.  
 
In a study of mothers with type 1 diabetes in Scotland, Penney et al identified the 
rate of congenital anomalies as 60 per 1000 total births, however there were no 
babies born with CL(P) from a sample of 273 pregnancies (107). Strengths of this 
study were its prospective design and the inclusion of pregnancies ending in 
miscarriage and abortion, as well as delivery. 
 
2.9.6 Maternal diabetes and OFC 
 
In the first study to specifically investigate the association between maternal 
diabetes and OFC, Spilson et al (2001) conducted a population based case-control 
study using the 1996 National Centre for Health Statistics United States Natality 
Database. Diabetic mothers were 1.352 times more likely than non-diabetic mothers 
to have a newborn with CL(P) (95% CI, 1.004-1.821; P<0.05). They did not 
differentiate between forms of diabetes or separately analyse different types of cleft, 
and the authors suggested that future should also include information on the 
modality of treatment for diabetes (3). 
 
Carinci et al studied 126 infants born with non-syndromic OFC in Southern Italy , 
and using univariate analysis, found that familial diabetes was associated more 
often with isolated CP than other forms (P=0.0014), however the sample was 
reasonably small and no control group was included (108).  
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Evers et al concluded that even near-optimal maternal glucose control is not 
adequate in the prevention of congenital anomalies including OFC, as their 
incidence in planned pregnancies is significantly lower than in unplanned 
pregnancies (109). Suhonen et al also stressed that ‘normoglycaemia should be 
strived for during early pregnancy’ as even slightly raised HbA1c in early pregnancy 
was found to increase the risk of birth defects in the Southern Finnish population 
(110). A systematic review by Wahabi et al concluded that preconception care is 
effective in reducing diabetes related congenital anomalies and Mossey et al found 
that in a UK-based study planned pregnancies were associated with a lower risk of 
OFC (111,112). 
 
2.9.7 Maternal overweight and congenital anomalies  
 
Obesity is an important and growing concern to public Health across the globe. 
Worldwide, the number of overweight (body mass index [BMI] 25-30, calculated as 
weight in kilograms divided by height in metres squared) and obese (BMI ≥30) 
adults is expected to be 2.3 billion and over 700 million respectively, by 2015 (113). 
In the USA, 50% of women aged 15-49 are currently overweight or obese (114), 
while in Australia 22.6% of 25-34 year old women were overweight, and 12.4% 
obese, in 2000 (115). 
 
Pre-pregnancy maternal obesity has significant health implications for both mothers 
and their babies, including the incidence of congenital anomalies. Abdominal 
adipose tissue accumulation associated with diabetic pathogenesis may be the 
underlying mechanism for the link between obesity and such birth defects. 
Interestingly, Shaw and Carmichael found that in a Californian population there was 
an association between diabetogenic metabolic pathogenesis and obese women 
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with weight gain around the waist, but not for women with weight gain on the hips 
(116). 
 
In a study of almost 23,000 pregnant women, Moore et al found that individually, 
obese women (BMI≥30) and women with pre-existing diabetes or GDM had no 
excess overall risk of having a baby with a major birth defect (prevalence ratios 0.95 
and 0.98 respectively) however where women were both diabetic and obese, there 
was a 3.1 times greater risk of major congenital anomalies. Therefore this suggests 
a synergistic interaction between diabetes and obesity in the pathogenesis of 
congenital anomalies (117). 
 
Martinez-Frias et al carried out a study using data from the Spanish Collaborative 
Study of Congenital Malformations (ECEMC) and found that in a group of mothers 
with GDM, obesity (BMI≥30) was associated with a significant increase in the risk of 
cardiovascular defects when compared to non-diabetic mothers. In mothers with 
normal glucose tolerance (NGT) pre-gestational BMI was not associated with 
congenital anomalies (118). This study utilised pre-pregnancy BMI which was 
ascertained through post-partum interview and may not be reliable. There was 
slightly less than one control mother per case, although the sample size was large, 
with over 30 000 in each group. 
 
Waller et al found a ‘weak to moderate’ association of maternal obesity with some 
birth defects including cleft palate in a study of over 10,000 women, excluding those 
with pre-existing diabetes (119). Biggio Jr et al concluded that maternal weight 
alone is not associated with an increased risk of congenital anomalies; however pre-
gestational diabetes is (120). This cross-sectional study included almost 42 000 
births, and where information regarding maternal BMI was unavailable, those 
weighing over 200lbs at their first pre-natal visit were defined as obese. 
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Parker et al looked at the association between high maternal dietary glycaemic 
index (DGI) and birth defects, and excluded women with pre-existing diabetes and 
GDM. They found an association between high DGI (based on a questionnaire) and 
CLP (adjusted OR, 1.23).  They also describe evidence of a synergistic effect of 
high DGI and obesity in selected birth defects, suggesting that while high DGI is 
associated with an increased risk of several birth defects, obesity combined with 
high DGI may increase this risk further (121). 
 
2.9.8 Maternal overweight and OFC 
 
A study by Cedergren and Kallen found a positive association between maternal 
obesity (BMI≥29) in early pregnancy and OFC (OR, 1.30) and that this risk was 
higher where clefting was associated with other major malformations (122). This 
study included a very large control group and there was a high level of 
completeness of reporting of BMI data in the registries utilised. 
 
 In another Swedish study of 220,328 mothers, Villamor et al found that among 
women whose second-pregnancy BMI was ≥3 units higher than their first-pregnancy 
BMI, the adjusted risk of isolated CP was 2.3 times higher, however increased BMI 
was not related to risk of CL. Long interpregnancy intervals also appeared to be 
associated with increased risk of CP (123). The authors found that almost three 
quarters of the pregnancies documented in the Swedish Birth registry were found to 
have complete data regarding maternal height and weight early in pregnancy.  
 
In a case-control study in Western Australia, Oddy et al concluded that mothers with 
pre-pregnancy obesity (BMI≥30) had a two-fold increased odds of having a baby 
with OFC (115). Maternal pre-pregnancy weight and height were self-reported 
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through a questionnaire. Live births, still births and terminations of pregnancy were 
included in this study. 
 
Stott-Miller et al carried out a population-based case-control study of infants with 
OFC (n=2153) and control infants (n=18070). They found that obese (BMI≥30) 
mothers had a ‘small increased risk’ of non-syndromic OFC in offspring compared to 
women of healthy BMI (adjusted OR, 1.26). Overweight (BMI≥25 and <30) mothers 
had an elevated odds of CL/P but not of isolated CP. Additionally, odds of non-
syndromic CL/P is 23% higher for each 10-point increase in maternal BMI (4). The 
authors reported a potentially significant limitation of a considerable amount of 
missing data for maternal BMI and pre-pregnancy weight. However they did carry 
out a secondary analysis with imputation of missing data in order to reduce the 
effect of bias. 
 
In a study of over 1 million births in Sweden, Blomberg and Kallen found that 
maternal pre-pregnancy morbid obesity (BMI≥40) is associated with OFC (OR 1.90) 
(124). The availability of data regarding maternal BMI was high, with maternal pre-
pregnancy weight and height reported for 85%. An advantage of this study was 
accessibility to a large-scale population register, increasing the statistical power of 
reported results. 
 
 A recent study by Marengo et al found the risk of birth defects including CL(P) to be 
‘substantially’ increased in obese mothers in a Texan population (125). This was 
also a large scale study, covering around 1.6 million births and utilising self-reported 
maternal pre-pregnancy height and weight. 
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A summary of the meta-analysis by Stothard et al (113) is illustrated in figure 11. 
This indicates the higher risk of OFC occurring in the offspring of obese mothers. 
 
Figure 11: Meta-analysis of maternal obesity and OFC, adapted from (Stothard 
et al, 2009 (113)) 
 
 
2.9.9 Summary and conclusions from this section 
 
The number of women with diabetes and who are overweight or obese is increasing 
worldwide, with an increased risk of offspring having CL(P) and numerous other 
congenital anomalies seen to be positively associated with both of these factors. 
 
Mothers with established diabetes may be at greater risk than those with gestational 
diabetes mellitus. The mechanism implicated in causing such birth defects may be 
related to maternal hyperglycaemia and impaired glucose metabolism during 
pregnancy leading to oxidative stress within the developing embryo. Because 
gestational diabetes develops towards the latter stages of pregnancy, while OFC 
develops within the first two months, the discrepancies in results between GDM and 
Study
Cases
(obese / rBMI)
Non-cases
(obese / rBMI)
Orofacial Clefts
Odds Ratio
(95% CI)
Weight
(%)
Blomberg and Källén (2010) 232 / 1132 106380 / 659361 1.27 (1.10-1.46) 37.9
Oddy et al (2009) 6 / 22 30 / 229 2.07 (0.78-5.53) 0.8
Rankin et al (2010) 11 / 22 4932 / 21146 1.64 (0.80-3.39) 1.4
Stott-Miller et al (2010) 191 / 540 1452 / 4829 1.18 (0.99-1.40) 24.7
Villamor et al (2008) 36 / 202 20516 / 139956 1.22 (0.85-1.73) 6.0
Waller et al (2007) 269 / 922 572 / 2241 1.14 (0.97-1.35) 28.1
Watkins et al (2003) 8 / 59 36 / 212 0.80 (0.35-1.81) 1.1
Overall (I2 = 0.0%) 753 / 2899 (Fixed Effect) 1.21 (1.11-1.32) 100.0
1
Higher odds in 
obese
Lower odds in 
obese
0.5 2 40.25
49 
 
 
 
established diabetes may not disprove the theory that impaired glucose metabolism 
is linked to development of OFC (4) . 
 
It would appear that both maternal hyperglycaemia and obesity are risk factors for 
congenital anomalies including OFC individually; however the relative risk may be 
increased when they are combined together synergistically. Different patterns of 
maternal weight gain may affect the risk of birth defects including OFC. There may 
also be aetiological differences related to CP and CL. 
 
The studies detailed have provided valuable evidence and insight into the roles of 
maternal diabetes and obesity in the development of congenital anomalies including 
OFC, and their findings must be supported and strengthened by further 
collaborative studies to elucidate both environmental and genetic risk factors 
contributing to OFC and the interactions between them. The positive role of pre-
pregnancy planning including the management of hyperglycaemia and maternal 
weight should also be the focus of future work toward preventive strategies. 
 
 
2.10 Relevance to the current project 
 
The significant body of work suggesting an aetiological role of both maternal 
diabetes and obesity in the development of OFC provides incentive to further 
investigate this link in our own population. The valuable resource of the CLEFTSiS 
database and other registries held within NHS Tayside provide scope for a linkage 
study, which may inform future Scotland-wide or even further reaching studies of 
these possible associations. This will have an informative effect on possible 
prevention strategies for OFC. 
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CHAPTER THREE: AIMS AND HYPOTHESES 
 
3.1 Aim 
 
The aim of this study was to investigate the association between oral cleft in 
children and diabetes and obesity in their mothers in the Tayside population. 
 
3.2 Longer term aims 
 
This study was designed as a pilot to a potential larger study (a) in certain European 
countries already identified through the European Science Foundation (ESF) and 
(b) In India where, via an NIH planning grant the following hypotheses will be tested: 
(1) Impaired glucose tolerance and diabetes are each associated with risk of oral 
clefts; (2) Impaired 1-CM and impaired glucose tolerance or diabetes interact to 
increase risk of oral clefts. 
 
3.3 Null hypotheses 
 Maternal diabetes confers no increase in the risk of children being born with 
cleft lip and/or cleft palate in the population of Tayside 
 Maternal obesity confers no increase in the risk of children being born with 
cleft lip and/or cleft palate in the population of Tayside 
 The information held within the CLEFSiS dataset and other maternal 
datasets within NHS Tayside has a high level of completeness which is 
required for accurate assessment and linkage 
 
The amount and quality of the data must allow for meaningful analysis between the 
case and control mothers, and ideally include sufficient information regarding 
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confounding factors in order to separate their influence from that of the independent 
variables. 
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CHAPTER FOUR: MATERIALS AND METHODS 
 
The unique circumstances within Tayside, featuring the existence of the Health 
Informatics Centre with access to both the CLEFTSiS database and other datasets 
of maternal information within NHS Tayside, enabled a record linkage study to be 
carried out. 
 
This study involved no patient-identifiable information, as all data were linked using 
the Community Health Index (CHI) number. Therefore no ethical approval or 
Caldicott Guardian approval was required. The study was sponsored by Tenovus 
Scotland. 
 
A sample size calculation was not performed as this was a pilot study, data for all 
case mothers within the available date range was included and the sample size 
would be limited to this number of mothers regardless of whether a calculation was 
carried out. 
 
4.1 The Health Informatics Centre  
 
The Health Informatics Centre (HIC) is a University research support unit operating 
within the college of Medicine, Dentistry and Nursing at the University of Dundee, in 
collaboration with NHS Tayside. HIC provides data users with linked anonymised 
information from population based health datasets, mainly from the NHS and the 
University of Dundee. Most datasets already have patient unique identifiers (CHI 
numbers) however HIC additionally adds unique identifiers to datasets that lack 
them. 
 
53 
 
 
 
Access to the anonymised individual data for analysis is provided within the HIC-
based ‘Safe Haven’ environment. Data users log on remotely to a secure server 
located within HIC in order to access data and perform analyses. Data cannot be 
copied or removed from the secure central server. 
 
The remote-access Safe Haven utilises the Citrix Xen Desktop secure environment. 
This is widely used by the military and government to provide secure access to 
information. Data are not released externally to data users, rather they are placed 
on a server at HIC within a secure IT environment, and the data user is given 
secure remote access for analysis. 
 
To enable an output data file to be removed from the Safe Haven, the data user 
moves the file to the output directory within their Safe Haven personal directory. The 
output file(s) are reviewed by a HIC Data Analyst between 9 -11 am the next 
working day, and once verified as not containing any patient-identifiable information, 
they are then emailed to the data user. 
 
4.2 HIC Data Requirement 
 
For this project, HIC initially identified a list of babies with OFC from the CLEFTSiS 
database born between 1990-2010, within the Tayside area. These were then given 
an anonymised patient identifier (PROCHI) based on their CHI number. 
 
Exclusion of records 
 
Syndromic and atypical clefts were excluded from the cohort sample. This was due 
to the believed differences in aetiology between non-syndromic OFC and syndromic 
and atypical clefts. The exclusion criteria were applied by removing any data 
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regarding babies with a positive entry in the column ‘cleft syndrome name’ within the 
Microsoft excel database. 
 
Inclusion criteria 
 
All babies born with non-syndromic OFC recorded within the CLEFTSiS database, 
born between 1990 and 2010 within Tayside, where no exclusion criteria applied. 
 
4.3 Identification of maternal data 
 
HIC identified the mothers of the babies selected from CLEFTSiS through the 
SMR02 database. SMR02 is a dataset of maternity inpatient and day cases. It 
contains data covering the whole of Scotland and includes information regarding 
mother and baby characteristics, birth weight, gestational age, mode of delivery and 
outcome of pregnancy. The dataset contains the mother and baby’s CHI numbers. 
 
4.4 Maternal data supplied 
 
The following datasets were provided by HIC regarding the cohort of mothers of 
babies with OFC: 
 
SMR02 
SCI-DC   –      Demography 
                 Body Mass Index  
HbA1c (blood glucose level) – taken in the first trimester of   
pregnancy (as per previous studies, (100,110) 
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4.4.1 SCI-DC 
 
The Scottish Core Information – Diabetes Collaboration (SCI-DC) contains the 
Scottish Diabetes Core Dataset as part of a national framework with the aim of 
supporting regional Managed Clinical Networks for diabetes by providing IT support, 
clinical information and data for national and local audit programmes. The datasets 
are developed and maintained by the SCI-DC Development Team based in the 
Clinical Technology Centre at Ninewells Hospital, Dundee. 
 
The following datasets were supplied: 
 
 
Table 4: SCI-DC Demography 
 
Field Description 
PROCHI 10 digit anonymised CHI generated by HIC. The first 3 digits 
are character, the last 7 are integers e.g. abc1234567 
Anon_date_of_birth Anonymised date of birth 
Date_in Date a person came into the health board region 
Date_out Date a person left this health board 
TYPE_DM Code identifying type of diabetes e.g. 1=Type 1 
TYPE_DM_Descriptor Descriptive text of type of diabetes e.g. Type 1 
DtDiag Date person was diagnosed with diabetes 
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Table 5: SCI-DC HbA1c 
 
Field Description 
PROCHI 10 digit anonymised CHI generated by HIC. The first 3 digits 
are character, the last 7 are integers e.g. abc1234567 
Test_date When HbA1c was performed 
Result_DCCT DCCT result (%) 
Test ID Indicates type of test e.g. 9=DCCT 
DataSource_ID ID of where test was performed 
DataSource_Description Description of where the test was performed 
 
 
 
Table 6: SCI-DC BMI 
 
Field Description 
PROCHI 10 digit anonymised CHI generated by HIC. The first 3 digits 
are character, the last 7 are integers e.g. abc1234567 
Date When BMI was taken 
Height Patient height (metres) 
Weight Patient weight (kgs) 
BMI Calculated from weight/height. Where this is blank, HIC will 
calculate it from the supplied heights/weights 
DataSource_ID ID of where test was performed 
DataSource_Description Description of where the test was performed 
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4.5 Level of deprivation 
 
The level of deprivation of the mothers was identified from the demography datasets 
provided using the Scottish Index of Multiple Deprivation (SIMD). This is an index 
linked to postcode and is a key tool for identifying area concentrations of 
deprivation. It is used for a wide range of purposes including as a statistical 
classification and as an indicator to target resources and policies at small areas. It 
also feeds into work looking at health inequalities across Scotland (Scottish 
Government). 
 
The SIMD covers the whole of Scotland, which is broken down into 6505 datazones. 
These datazones are grouped into five categories, which range from 1 being ‘most 
deprived’ to 5 being ‘least deprived’. 
 
Figures 11, 12 and 13 show the population structure of each Tayside locality by 
SIMD category. The charts demonstrate that the Dundee has the largest deprived 
population across Tayside’s three local authority areas. (NHS Tayside) 
 
 
Figure 12: Deprivation profile: Angus 
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Figure 13: Deprivation profile: Dundee City 
 
 
 
Figure 14: Deprivation profile: Perth and Kinross 
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4.6 Control sample 
 
Four control mothers for each case mother were randomly selected from the 
SMR02 dataset by HIC. It was felt that this would increase the statistical power of 
the results. These mothers had a date of delivery +/- 3 months from the case births, 
and were also matched on age at delivery. All controls were resident in Tayside at 
the time of the birth and had been for at least one year prior to the birth. 
 
The control group consisted of 564 mothers, based upon an original group of 141 
case mothers prior to only the unique patients being isolated. The datasets provided 
regarding the control mothers were the same as for the cases, but supplied within 
separate files. 
 
 
4.7 Data management 
 
Datasets were supplied by HIC in Microsoft Excel spreadsheet format (Microsoft, 
Redmond, California, USA). Where datasets included more than one test result for 
the same mother, they were individually searched and the date most closely 
corresponding with the date of delivery extracted. Statistical analysis was then 
performed using IBM SPSS Statistics software version 21 (IBM corp., NY, USA) 
after the files had been converted to this format. 
 
 
4.8 Statistical analysis 
 
All statistical analyses were performed using the SPSS programme. This was 
following advice and assistance from a medical statistician. 
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Comparison between the proportion of mothers with known diabetes within the case 
and control groups was made using the Mantel-Haenszel Common Odds Ratio 
Estimate following data entry into a 2x2 table. This assumed that the population of 
the sample groups had a normal distribution and assessed categorical data 
(diabetes = either ‘yes’ or ‘no’). 
 
The independent samples t-test assuming unequal sample size and unequal 
variance was utilised to analyse the numerical data relating to the mean weight and 
blood glucose levels (HbA1c) of the case and control mothers. 
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CHAPTER FIVE: RESULTS 
 
A total of 138 case mothers and 564 control mothers were included in this study. 
These were identified following elimination of any duplicates and supplied by HIC. 
All data were regarding live births as abortions are not reported in the CLEFTSiS 
dataset. 
 
 
 
 
5.1 Age of mothers 
 
The case and control mothers were matched on age at delivery as well as date of 
delivery. The demographics are demonstrated in table 9: 
 
Table 7: Age of mothers at delivery 
 Minimum age Maximum age Mean age Standard 
deviation 
Cases 18 45 28.9 5.63 
Controls 18 44 28.8 5.76 
141 case mothers 
identified from 
CLEFTSiS dataset 
Removal of 
duplicates (n=3) 
138 case mothers 
given anonimysed 
CHI number 
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5.2 Level of deprivation 
 
The level of deprivation of the mothers linked to postcode using the Scottish Index 
of Multiple Deprivation (SIMD) was identified from the SMR02 dataset. A SIMD 
score was found to be recorded for 129/138 case mothers and 5454/564 control 
mothers. 
 
Table 8: Frequency and percentage of SIMD scores: case mothers 
SIMD score Frequency % 
1 27 20.9 
2 15 11.6 
3 22 17.1 
4 41 31.8 
5 24 18.6 
Total 129 100 
 
 
Table 9: Frequency and percentage of SIMD scores: control mothers 
SIMD score Frequency % 
1 93 17.1 
2 84 15.4 
3 100 18.3 
4 157 28.8 
5 111 20.4 
Total 545 100 
 
 
Table 10: SIMD scores: case and control mothers 
SIMD score Cases Controls Total 
1 27 93 120 
2 15 84 99 
3 22 100 122 
4 41 157 198 
5 24 111 135 
Total 129 545 674 
 
Chi-squared test significance: 0.828 
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5.3 Types of clefting  
 
The phenotype of OFC affecting the babies of the mothers in the case group was 
recorded. 
 
Table 11: Frequencies of OFC phenotype 
 
Phenotype Frequency % 
BCL 3 2.2 
BCLP 6 4.4 
UCL 37 26.3 
UCLP 28 20.6 
CP 63 45.8 
CL 1 0.7 
Total 138 100 
 
One case was recorded as having ‘CL’ with no indication of laterality. 
 
Of the 63 cases with CP only recorded, 38 (60%) were female. Of the 75 cases 
recorded as having CL/ P, 32 (43%) were female. 
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5.4 Comparison of prevalence of diabetes within the case and control groups 
 
Within the group of 138 case mothers, 4 were identified as having diabetes from the 
SCI-DC dataset. Within the control group of 564 mothers, 13 were identified as 
being diabetic. 
 
Only 1 of the 4 diabetic case mothers and 2 of the 13 diabetic control mothers had a 
data entry for date of diagnosis with diabetes. 
 
 
Table 12: Prevalence and type of diabetes affecting case and control mothers 
 
 Type of diabetes Total 
Type 1 Type 2 Other 
Cases 2 1 1 4 
Controls 6 6 1 13 
Total 8 7 2 17 
 
 
Table 13: 2x2 table of diabetes prevalence 
 
 Diabetic Non-diabetic Total 
Cases 4 134 138 
Controls 13 551 564 
Total 17 685 702 
 
 
Mantel-Haenszel common odds ratio estimate: 1.265 
95% Confidence interval of common odds ratio: 0.406-3.942 
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Table 14: Chi-squared test comparing prevalence of diabetes 
 
N of diabetic 
case mothers 
N of diabetic 
control 
mothers 
Significance 95% 
confidence 
interval 
Odds ratio 
4 13 0.6305 0.3611, 3.903 1.304 
 
Significance was set at p < 0.05 
 
 
5.5 Comparison of blood glucose levels (HbA1c) 
 
Within the SCI-DC datasets, measurements of glycosylated haemoglobin had been 
recorded as standardised units against the 1993 Diabetes Control and 
Complications trial (DCCT). The DCCT unit is recorded as HbA1c %. The DCCT 
value taken in the first trimester of pregnancy for each mother was identified and the 
mean value calculated. 
 
 
Table 15: Mean HbA1c values of diabetic case and control mothers 
 
 Number Minimum 
HbA1c(%) 
Maximum 
HbA1c(%) 
Mean 
HbA1c(%) 
Standard 
deviation 
Cases 4 6.5 11.0 7.975 2.069 
Controls 13 5.2 9.6 6.846 1.475 
 
 
Table 16: Independent samples t-test for equity of mean HbA1c 
 
Mean HbA1c 
cases 
Mean HbA1c 
controls 
Significance 95% Confidence 
interval 
7.975% 6.846% 0.368 -4.222, 1.964 
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5.6 Comparison of maternal BMI 
 
There were found to be large deficiencies with data entries in the SCI-DC BMI 
dataset, with none of the diabetic case mothers having an entry, and only one of the 
diabetic control mothers having a recorded BMI, which was not close in date to that 
of delivery. Therefore maternal weight recorded at the date closest to the date of 
delivery was identified from the SMR02 dataset and compared between case and 
control mothers. There was insufficient data regarding height and weight to 
calculate BMI. 
 
Weight (kg) had been recorded at the time of admission for delivery for 21/138 case 
mothers and 89/564 control mothers. 
 
Table 17: Mean weight  
 Number Minimun 
weight 
(kg) 
Maximum 
weight 
(kg) 
Mean 
weight (kg) 
Standard 
deviation 
Cases 21 47 132 71.05 20.996 
Controls 89 49 138 75.08 20.394 
 
 
Table 18: Independent samples t-test for equity of mean weight 
 
Mean weight case 
mothers  
Mean weight 
control mothers  
Significance 95% Confidence 
interval 
71.05 kg 75.08 kg 0.418 -14.378, 6.316 
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CHAPTER SIX: DISCUSSION 
 
6.1 Sample numbers, completeness of datasets and confounding factors 
 
Data regarding a total of 138 case mothers and 564 control mothers were available 
for analysis; however the numbers of mothers recorded as being diabetic was low at 
4/138 and 13/564. This prevented further analysis of the differing categories of 
diabetes between groups. 
 
 It was discovered during examination of the CLEFTSiS, SMR02 and SCI-DC 
datasets that information regarding the mothers in the sample was frequently 
missing. There was insufficient data to calculate and analyse maternal BMI, 
therefore maternal weight was analysed instead. This is not the ideal measurement 
to investigate associations with maternal obesity. 
 
The smoking and alcohol status of the mothers in the CLEFTSiS dataset was 
recorded in 62 of 138 cases (45%), while in the SMR02 dataset smoking status was 
only recorded for 98 of the 564 control mothers (17%). It was therefore not possible 
to analyse these potential confounding factors. 
 
6.2 Maternal age at delivery 
 
As case and control mothers had been matched on age at delivery, it was 
unsurprising that their mean ages at delivery were very similar at 28.9 and 28.8 
years respectively. The case mothers’ age at delivery ranged from 18 to 45 years. 
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6.3 Maternal level of deprivation 
 
The SIMD scores, linked to postcode, of the case and control mothers at the time of 
admission for delivery were not significantly different (p = 0.828). The highest 
proportion of both groups were SIMD score 4 (31.8% case mothers and 28.8% of 
control mothers).  
 
Both groups had similar numbers in each SIMD category, reflecting the general 
distribution of population in Tayside, with most females in the Angus and Perth 
areas in SIMD category 4, while the slightly raised number of both case and control 
mothers in SIMD category 1 is reflective of the Dundee City population. 
 
6.4 Types of clefting 
 
Within the sample group of babies born with OFC in Tayside, 45.8% were 
documented as having isolated CP. This is higher than the 20-25% reported in 
European and US studies (1). The perceived differences in aetiology between CP 
and CL/P may therefore be relevant in the Tayside population. 
 
Isolated CL made up 29% of the sample group, which is comparable to the 20-25% 
seen in these larger studies. Cases of CLP made up 25% of the sample, which is 
lower than the 30-35% reported there. 
 
Within the CLP group in this study, 82% had a unilateral cleft and 18% of clefting 
was bilateral, which is very similar to the 80% and 20% reported in the larger 
studies. 
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Of the 63 recorded cases with CP only, 38 (60%) were female, which is in 
accordance with the reported female predominance in CP (86). Of the 75 cases 
recorded as having CL/ P, 32 (43%) were female, which is higher than the 2:1 
male:female ratio generally found in white populations (12). 
 
6.5 Prevalence of diabetes 
 
Within the control group, 2.3% (13/564) of mothers were documented as having 
diabetes. This is reduced in comparison to the 4.7% of the Scottish and 5% of the 
Tayside populations with diabetes (126). This may be attributable to the relatively 
young age of these women at delivery compared to the increasing age of the 
general population and the morbidities associated with this including diabetes. 
 
2.9% of the case mothers were diabetic, again low in comparison to regional and 
national figures. This figure was similar to the 3.6% found by Spilson et al in a larger 
US population sample (3), therefore this Tayside sample may well be representative 
of both national and international populations. 
 
There was no significant difference between the prevalence of diabetes in the case 
and control groups (OR 1.265, 95% Confidence interval: 0.406, 3.942, p = 0.6305), 
therefore a link between maternal diabetes and OFC in their offspring could not be 
identified within the Tayside population. The sample size was, however, limited and 
the potential for selection bias exists as it cannot be guaranteed that all patients 
diagnosed with diabetes are registered in the SCI-DC dataset. 
 
There was also poor reporting of the date of diagnosis with diabetes within the SCI-
DC dataset. Only 1 of the 4 case mothers with diabetes and 2 of the 13 control 
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mothers had a positive entry for date of diagnosis. This prevented further analysis 
based upon duration of diabetes history. 
 
6.6 Comparison of blood glucose levels (HbA1c) 
 
There was no significant difference between the mean HbA1c of the case and 
control mothers who were recorded as being diabetic in the SCI-DC dataset. Both 
were elevated at 7.975% and 6.846% respectively, in comparison to the healthy 
reference range of 4-5.9%. 
 
Suhonen et al found that even a slightly elevated HbA1c of 6.8% in women was 
linked to a relative risk of 3.0 for major foetal malformations (110), while in a study 
by Towner et al, mothers who had offspring with major congenital malformations 
were found to have a mean HbA1c of 9.5% (100). 
 
Although no difference was identified between the groups in this study, it seems that 
in light of the increased risk of congenital malformations associated with raised 
HbA1c in other studies, an important role for pregnancy planning and the 
achievement of normoglycaemia must be emphasised. 
 
6.7 Comparison of maternal weight 
 
The original intention in this study had been to assess any potential difference in 
body mass index (BMI) between the case and control mothers in order to ascertain 
whether there was a link between maternal overweight/obesity and OFC. 
 
Unfortunately data regarding maternal weight and particularly height was poorly 
reported and therefore was insufficient to calculate BMI. Maternal weight recorded 
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as near as possible to the date of delivery was identified from the SMR02 dataset. 
This is not an ideal indicator of the mother’s overweight/obesity status as it does not 
take account of height, unlike BMI. 
 
There was no significant difference in mean weight between the case (71.05 kg) 
and control (75.08 kg) mothers and both were above the Scottish average for 
women of 64.8 kg (127). Again, the numbers analysed were small so this does not 
therefore exclude the possibility of a positive association between maternal obesity 
and OFC. Initially it does appear that within this sample there was a tendency to be 
overweight, however this reflects the fact that the recording of weight was at the 
time of birth of the index child. 
 
6.8 Strengths of this study 
 
One of the main strengths of this study has been its originality within the Scottish 
population, building on work carried out elsewhere worldwide. The processes 
undertaken and the problems encountered will allow us to develop strategies to 
analyse larger population groups. The unique availability of both the CLEFTSiS 
dataset and datasets covering maternal information, which could then be linked 
together allowed this study to be performed for the first time in Scotland and will act 
as a pilot for future research in this area. 
 
As this study was population-based and utilised data covering a considerable period 
of time, it is therefore relatively robust against selection bias. The extremely positive 
presence of the HIC team and their ability to provide a substantial group of matched 
controls was a great advantage in this study. 
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6.9 Weaknesses 
 
Although all babies born with OFC between 1990 – 2010 were included in this 
study, this still gave a relatively small sample size, particularly when considering 
that only around 5% of individuals in the Scottish population are diabetic. The 
results therefore may not be representative of the whole Scottish population. 
 
The CLEFTSiS database is an accurate record of births with OFC, however there is 
a potential source of information bias where some cases of isolated CP may not 
have been diagnosed at birth and therefore not recorded in the dataset. 
 
Another limitation of this study was that cleft types could not be analysed separately 
due to low numbers. Different types of OFC may have differing aetiological bases 
and this effect will be masked where the groups are analysed together. 
 
The datasets were found to be incomplete in some areas, particularly regarding the 
potential confounding factors of smoking and alcohol intake. This means that their 
effect could not be separated. Maternal BMI could not be analysed due to poor 
reporting of BMI, height and weight. 
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CHAPTER SEVEN:  CONCLUSIONS AND RECOMMENDATIONS 
 
The null hypothesis that the information held within the CLEFTSiS dataset and other 
maternal datasets within NHS Tayside has a high level of completeness which is 
required for accurate assessment and linkage must be rejected, as data sets were 
found to be poorly populated with data regarding several maternal characteristics, 
including smoking status and BMI. 
 
The null hypothesis that maternal diabetes confers no increase in the risk of children 
being born with cleft lip and/or cleft palate in the population of Tayside, Scotland, 
must be accepted in this study. 
 
The null hypothesis that maternal obesity confers no increase in the risk of children 
being born with cleft lip and/or cleft palate in the population of Tayside, Scotland, 
must also be accepted in this study. 
 
Larger population-based database linkage studies would be indicated to ascertain 
whether a positive association between maternal diabetes and obesity and OFC 
exists in the Scottish population, as it is seen to in other population groups. The 
CLEFTSiS dataset is an invaluable source of information in the pursuit of this goal; 
and the CHI system in Scotland that allows record linkage to other relevant medical 
data has made this study possible. 
 
This pilot project revealed a surprisingly low prevalence of reported diabetes among 
mothers of children with clefts of the lip and palate. As a result the numbers of 
mothers of CLP patients or CP patients that had a diagnosis of type 1, Type 2 or 
74 
 
 
 
gestational diabetes was extremely small and rendered the study under powered 
and therefore subject to statistical error.  
  
Based on these results, a power calculation would enable a more reliable estimate 
of the size of the population and the number of clefts required to determine whether 
there is any relationship between maternal diabetes and the risk of having a child 
with a cleft lip and/ or palate. 
 
However, as there were found to be large discrepancies in the completeness of the 
data sets analysed, there is a lack of robust data upon which to base a larger study 
at present. Prior to any such study being undertaken, datasets would require 
inspection to ensure that they are comprehensive enough to enable meaningful 
analysis. Including a larger volume of data by extending the timescale of data 
collection may be possible in the future. 
 
Hospital-based databases must be fully complete where possible. This will rely on 
accurate and conscientious recording of maternal information at a clinical level, and 
therefore requires adequate provision of time and staff training. 
 
Future studies should include more detailed information regarding: 
 
 Confounding factors including smoking and alcohol intake 
 Descriptive maternal information including BMI and type of diabetes 
 The inclusion of all births with OFC – live, aborted and stillborn 
 
This will allow a more accurate and detailed assessment of a possible association 
between maternal diabetes and obesity and OFC. 
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A worldwide effort to form a network of registries and research projects in both 
developed and developing countries is key in elucidating the importance of 
aetiological factors involved in the development of OFC. This will involve 
collaboration in order to achieve the large numbers required to tackle heterogeneity 
and find a true answer to our questions. The ultimate aim will be to obtain sufficient 
information on both genetic and environmental factors influencing OFC outcomes to 
enable strategies on primary prevention. 
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CHAPTER NINE: APPENDICES 
 
APPENDIX I 
CLEFTSiS NCAS Registration Form 
 
Registered with CLEFTSiS on ……………..   
NCAS Information Leaflet Provided 
Yes   No    
PATIENT DEMOGRAPHICS 
 
Surname……………………………… Address ……………………………… 
Forename……………………………… ……………………………………….. 
Gender    M     F        City ………………………………….. 
CHI Number ………………………… Postcode ……………………………... 
Date of Birth…. ……………………. Registered GP………………………… 
Telephone Number…………………… Allergies/Alerts ………………………. 
Cleft Number …………………………. Health Board…………………………. 
 
Ethnicity      
 Scottish  Bangladeshi, Bangladeshi 
Scottish/British 
 English  Chinese, Chinese Scottish/British 
 Welsh  Other Asian 
 Northern Irish  African, African Scottish/British 
 British  Caribbean, Caribbean 
Scottish/British 
 Gypsy/Traveller  Black, Black Scottish/British 
 Polish  Other African 
 White Any other ethic group  Arab 
 Any mixed or multiple ethnic group  Any other Ethnic 
 Pakistani, Pakistani Scottish/British  Refused/Not provided by patient 
 Indian, Indian Scottish/British  Not known 
 
CLEFT DETAILS (to be confirmed by Cleft Surgeon) 
(C=Complete,  I= Incomplete) 
              Patients Right                   Patients Left 
Lip C / I / Nil    C / I / Nil 
Alveolus  C / I / Nil  C / I / Nil  
Hard Palate   C / I / Nil   
Soft Palate   C / I / Nil   
Simonarts Band (not 
on NCAS - for info 
only) 
Yes/No    Yes/No 
Submucous Cleft   Yes       No      
Non Cleft VPI   Yes       No      
Other ……………………………… 
 
 
 
Address Label 
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LAHSHAL Code ……………………… (Record within patient demographics notes field) 
CLEFT Type:  BCL / UCL / CP / BCLP /  UCLP 
 
COMORBIDITY DETAILS 
Craniofacial Disorder      Yes      No      Other Medical         Yes      
No   
Di George Syndrome     Yes      No      Other Syndrome Recorded Yes      
No      
Pierre Robin Syndrome   Yes      No       (Record further details under Encounters/Genetics)    
 
REFERRAL DETAILS – FIRST CONTACT DETAILS 
Treatment Centre  ……………………… 
Date of Referral  ……………………… 
Date Referral Received ……………… 
Referral Source      Post natal      
        Ante natal      
        Late Referral 
      
Clinician In Charge (Cleft Surgeon) ……………………………………. 
 
Reason for Referral   ………………………………… 
Referred by      ………………………………… 
Referred from    …………………………………  
Referring Health Board  …………………………………  
 
Referral Outcome       Telephone call within 24 hours of referral      
        Visit to patient within 24 hours of referral 
Referral Outcome Date …………………………………… 
 
FAMILY HISTORY 
History of Cleft    
Mother    Yes      No      
Father    Yes      No      
Other   Yes      No     Specify Relationship ……………………… 
Consanguineous Yes      No     Specify Relationship ……………………… 
Male Siblings  Yes      No         
Female Siblings  Yes      No         
Twin affected  Yes      No         
 
PARENTAL DETAILS/PREGNANCY DETAILS/BIRTH HISTORY 
(not collected on NCAS – for information only) 
Parental Details 
Age of Mother  ……………………  Age of Father ………………….…  
Occupation of Mother ……………………   Occupation of Father  …………….. 
 
Pregnancy Details 
Alcohol Units per week …………..…  
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Drugs Give Details  …………..…  
Smoking No/per week ……………..  
Illnesses  Give Details  ……………..   
Trauma  Give Details  ……………..  
Vitamins/Herbal remedies  Give Details  ……………..   
 
Birth History 
Birth Number Single/Multiple  
Twin Type Identical/Non-Identical   
Twin Affected Gender   ………..    
Gestation Weeks ………..  
Head circumference ….... cm    
Weight at birth …… kg  
Length at birth ….... cm   
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APPENDIX II 
 
CLEFTSiS 
(National Managed Clinical Network for Cleft Services in Scotland) 
 
The CLEFTSiS Register records details of all patients in Scotland with cleft lip 
and/or palate.  The Register also contains the records which are required to 
monitor your child’s treatment and compare their outcome with others to ensure 
they are receiving the best treatment possible.  The register is maintained on 
behalf of CLEFTSiS by the Tayside University Hospitals NHS Trust.   
 
The information is confidential, and will be stored securely.  It will be linked 
through a unique CLEFTSiS number.  Only professional members of the Network 
will have access to it if they have a particular need to use the information.  
Access will be through the CLEFTSiS Administrator. 
 
The records taken include photographs, sound and video recordings of speech, 
dental impressions, and x-rays.  The records are stored as part of the Register 
and will be anonymised when they are used to compare their outcome with 
others.   
 
 
CONSENT FORM for inclusion on the CLEFTSiS Register and for Records 
 
Your child has been diagnosed as having a cleft lip/cleft palate/cleft lip and palate.  
Whatever type of cleft your child has it is important that he/she is seen regularly for check 
ups.  These check-ups will be arranged for him/her to be seen by different specialists at 
their hospital clinics or at a combined clinic.  With your permission, we would like to place 
details of your child on the CLEFTSiS register in order to:  
 
a. make sure that s/he is given appointments for regular check ups. 
b. share information about your child with other health professionals who are 
involved in their care. 
c. to plan services and help our understanding of the condition through audit 
under the control of the executive support research by providing anonymous 
information.  
 
 
Your are welcome to see what information is held on the register by contacting 
the CLEFTSiS Administrator at the address below, and you can ask for help in 
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understanding what it says.  There may be a charge for this in accordance with 
the subject access arrangements for the Data Protection    Act 1998.  You are 
free to have your child’s name and details removed from the register at any time, 
but it will mean we cannot use this information about your child to plan future 
services and to ensure that we do not lose contact with you. 
 
I do / do not consent to having my child’s name on the CLEFTSiS register. 
 
I do /do not consent to having CLEFTSiS records taken of my child. 
 
Child’s Full Name:…………………………………… 
DOB:………………………………. 
 
Parent’s Name:………………………………………. 
 
Address:………………………………………………. 
 
              ……………………………………………….. 
 
……………………………………………….. Postcode: ………………………. 
 
1st 
signature:……………………………………………Date:…………………………… 
(At birth or at first combined clinic) 
 
The CLEFTSiS registry is maintained at Perth Royal Infirmary by: 
The CLEFTSiS Network , Room 17, Admin Block, Perth Royal Infirmary PH1 1NX 
Tel:   01738 473508       Fax:  01738 473278 
  
 
